

December 16, 2025

Dear All,

Company Name : Delta-Fly Pharma, Inc.
(Code number : 4598 TSE Growth Market)
Inquiries : Kenzo Iizuka, Senior Vice President, R&D
(Contact: <https://www.delta-flypharma.co.jp/en/contactentrance/>)

Update DFP-10917 combo-therapy with VEN

1. Enrollment of all planned patients to Phase 1/2 combo-study of DFP-10917 with Venetoclax (VEN) in AML patients with one prior treatment by VEN involved regimen, has been completed.
In Phase 2 portion of Phase 1/2 study, duration of VEN was shortened from 2weeks to 10 days to prevent damage to the bone marrow by VEN without any change for DFP-10917 according to the investigator's recommendation. Data Monitoring Committee (DMC) shall evaluate efficacy and safety after follow-up treated patients for a certain period. An end of Phase 2 meeting with the FDA in US shall be held.

END